Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 0.84 |
| ▸ | GRIN1 | Q05586 | 20/20 | 0.84 |
| ▸ | GRIN2B | Q13224 | 20/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19219254 | 0.91 | GRIN1 (1.00) | RXRAGRIN1GRIN2B | |
| SCHEMBL19221789 | 0.90 | RXRA (1.00) | RXRAGRIN1GRIN2BKCNH2 | |
| SCHEMBL19219253 | 0.89 | GRIN1 (1.00) | RXRAGRIN1GRIN2B | |
| SCHEMBL19219250 | 0.88 | GRIN1 (1.00) | RXRAGRIN1GRIN2BKCNH2 | |
| SCHEMBL19219257 | 0.86 | GRIN1 (0.81) | RXRAGRIN1GRIN2BKCNH2 | |
| SCHEMBL19219165 | 0.86 | GRIN1 (1.00) | RXRAGRIN1GRIN2BKCNH2 | |
| SCHEMBL19219283 | 0.83 | GRIN1 (0.73) | RXRAGRIN1GRIN2BKCNH2 | |
| SCHEMBL19219172 | 0.82 | GRIN1 (1.00) | RXRAGRIN1GRIN2B | |
| SCHEMBL19211501 | 0.82 | GRIN1 (0.74) | RXRAGRIN1GRIN2BKCNH2 | |
| SCHEMBL19219162 | 0.82 | GRIN1 (1.00) | RXRAGRIN1GRIN2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226089-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226089-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | GRIN3A, GRIN3B, GRIN1 | RXRA 2100/4885GRIN1 3/4885GRIN2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.